The clinical TIL experience in melanoma: Past, present, future Review

  


Authors: Smithy, J. W.; Schoenfeld, A. J.; Betof Warner, A.
Review Title: The clinical TIL experience in melanoma: Past, present, future
Abstract: The recent approval of lifileucel by the US Food and Drug Administration in February 2024 was the culmination of over 3 decades of research in adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) for unresectable melanoma. In this review, we highlight key historical data for TIL therapy in melanoma as well as ongoing efforts to improve its efficacy and applicability. © 2024 The American Society for Transplantation and Cellular Therapy
Keywords: review; tumor associated leukocyte; lymphocytes, tumor-infiltrating; melanoma; history, 21st century; food and drug administration; pathology; history; history, 20th century; immunology; immunotherapy; adoptive transfer; therapy; adoptive immunotherapy; immunotherapy, adoptive; autologous; tumor infiltrating lymphocytes; humans; human; til therapy; lifileucel
Journal Title: Transplantation and Cellular Therapy
Volume: 31
Issue: 3 Suppl.
ISSN: 2666-6375
Publisher: Elsevier Inc.  
Date Published: 2025-03-01
Start Page: S626
End Page: S634
Language: English
DOI: 10.1016/j.jtct.2024.11.013
PUBMED: 40089331
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-105000032469&doi=10.1016%2fj.jtct.2024.11.013&partnerID=40&md5=6bf36f80e047fade171f78309c87ace8
Notes: Review -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Adam Jacob Schoenfeld
    137 Schoenfeld
  2. James William Smithy
    30 Smithy
Related MSK Work